% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bolsewig:276323,
author = {Bolsewig, Katharina and Willemse, Eline A J and
Sánchez-Juan, Pascual and Rábano, Alberto and Martínez,
Minerva and Doecke, James D and Bellomo, Giovanni and
Vermunt, Lisa and Alcolea, Daniel and Halbgebauer, Steffen
and In 't Veld, Sjors and Mattsson-Carlgren, Niklas and
Veverova, Katerina and Fowler, Christopher J and Boonkamp,
Lynn and Koel-Simmelink, Marleen and Hussainali, Zulaiga and
Ruiters, Daimy N and Gaetani, Lorenzo and Toja, Andrea and
Fortea, Juan and Pijnenburg, Yolande and Lemstra, Afina W
and van der Flier, Wiesje M and Hort, Jakub and Otto, Markus
and Hansson, Oskar and Parnetti, Lucilla and Masters, Colin
L and Lleó, Alberto and Teunissen, Charlotte E and Del
Campo Milán, Marta},
title = {{I}ncreased plasma {DOPA} decarboxylase levels in {L}ewy
body disorders are driven by dopaminergic treatment.},
journal = {Nature Communications},
volume = {16},
number = {1},
issn = {2041-1723},
address = {[London]},
publisher = {Springer Nature},
reportid = {DZNE-2025-00286},
pages = {1139},
year = {2025},
abstract = {DOPA Decarboxylase (DDC) has been proposed as a
cerebrospinal fluid (CSF) biomarker with increased
concentrations in Lewy body disorders (LBDs) and highest
levels in patients receiving dopaminergic treatment. Here we
evaluate plasma DDC, measured by proximity extension assay,
and the effect of dopaminergic treatment in three
independent LBD (with a focus on dementia with Lewy bodies
(DLB) and Parkinson's disease (PD)) cohorts: an
autopsy-confirmed cohort (n = 71), a large multicenter,
cross-dementia cohort (n = 1498) and a longitudinal cohort
with detailed treatment information (n = 66, median
follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not
altered between different LBDs and other disease groups or
controls in absence of treatment. DDC levels increased over
time in PD, being significantly associated to higher dosages
of dopaminergic treatment. This emphasizes the need to
consider treatment effect when analyzing plasma DDC, and
suggests that plasma DDC, in contrast to CSF DDC, is of
limited use as a diagnostic biomarker for LBD, but could be
valuable for treatment monitoring.},
keywords = {Humans / Lewy Body Disease: drug therapy / Lewy Body
Disease: blood / Lewy Body Disease: cerebrospinal fluid /
Dopa Decarboxylase: metabolism / Male / Female / Aged /
Parkinson Disease: drug therapy / Parkinson Disease: blood /
Parkinson Disease: cerebrospinal fluid / Biomarkers: blood /
Biomarkers: cerebrospinal fluid / Aged, 80 and over / Middle
Aged / Dopamine Agents: therapeutic use / Cohort Studies /
Longitudinal Studies / Dopa Decarboxylase (NLM Chemicals) /
Biomarkers (NLM Chemicals) / Dopamine Agents (NLM
Chemicals)},
cin = {Clinical Study Center (Ulm)},
ddc = {500},
cid = {I:(DE-2719)5000077},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39881147},
doi = {10.1038/s41467-025-56293-z},
url = {https://pub.dzne.de/record/276323},
}